IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation

Status unconfirmed · Phase 4

Conditions studied: Covid19, SARS-CoV Infection

In brief

The purpose of this Pilot Study is to establish a hypothesis of whether or not intravenous immunoglobulin (IVIG) may impact the hospital length of stay, if started within 48 of mechanical ventilation in patients infected with SARS-CoV-2 virus.

Key facts

Study ID

NCT04616001

Run by

Sharp HealthCare

People needed

10

Starts

2020-11-01

Expected to finish

2021-06-30

Last updated by the study team

2020-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed COVID-19 positive test result
• Initiation of the first dose of IVIG within 72 hours of mechanical ventilation.
• Age >18 years old.
• Consenting next of kin having access to an electronic device that is able to access DocuSign® online and email for consenting.
• Subjects or their proxy must have the ability to understand the requirements of the study, provide informed consent, and provide authorization of use and disclosure of personal health information.

You may not qualify if…

• Superimposed bacterial pneumonia or bacteremia
• Severe allergy to any IVIG product formulation
• Hypersensitivity to corn
• Uncontrolled hypertension (SBP>180 mm Hg or DBP>120mmHg)
• Active participant in another research treatment study
• Advanced dementia
• Severe renal disease (CrCl< 20 mL/min)
• Active cancer malignancy
• Active treatment with cancer chemotherapy or immunotherapy
• Congestive heart failure clinically or by history (EF< 25%)
• Prior receipt during admission of any other investigational agent (eg. convalescent plasma, tocilizumab)
• Venous or arterial thrombosis < 90 days prior
• Are receiving cytotoxic or biologic treatments such as TNF inhibitors, anti-interleukin-1 (IL-1), anti-IL-6 (tocilizumab or sarilumab), T-cell or B-cell targeted therapies (rituximab), interferon, or Janus kinase (JAK) inhibitors for any indication at study entry. Note: A washout period 4 weeks (or 5 half-lives, whichever is longer) is required prior to screening, with the following exceptions:
• B-cell targeted therapies: a washout period of 24 weeks or 5 half-lives (whichever is longer)
• TNF inhibitors: a washout period of 2 weeks or 5 half-lives (whichever is longer), and
• JAK inhibitor: a washout period of 1 week or 5 half-lives (whichever is longer).

Where it is running

• Sharp Memorial Hospital — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.